Ipsen SA and Inspiration Biopharmaceuticals Enter into an Asset Purchase Agreement with Baxter International Inc on OBI-1


Thursday, 24 Jan 2013 01:30am EST 

Ipsen SA and Inspiration Biopharmaceuticals Inc. (Inspiration) announced they entered into an Asset Purchase Agreement (APA) whereby Baxter International Inc (Baxter) agrees to acquire the worldwide rights to OBI-1, a recombinant porcine factor VIII (rpFVIII) in development for congenital hemophilia A with inhibitors and acquired hemophilia A, and Ipsen SA’s industrial facility in Milford (Boston, MA). Under the terms of the APA, Baxter has agreed to pay USD 50 million upfront, up to USD 135 million in potential additional development and commercial milestones as well as tiered net sales payments ranging from 12.5% to 17.5% of OBI-1 annual net sales. The sale process for IB1001, a recombinant factor IX (rFIX) for the treatment and prevention of bleeding in patients with hemophilia B is separate and in the final bidding stage. 

Company Quote

74.48
0.41 +0.55%
19 Dec 2014